3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
32
Metastatic Castration-resistant Prostate Cancer
3
Prostatic Neoplasms, Castration-Resistant
2
Prostate Cancer Metastatic
2
Urogenital Neoplasms
1
Sleep Initiation and Maintenance Disorders
1
Prostatic Diseases
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
NSCLC Harboring NRG1 Fusion
1
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
1
Metastatic Castration-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
Male Urogenital Diseases
1
Genital Neoplasms, Male
1
Fatigue
1
Depression
1
Advanced Prostate Cancer
1
Interventions
darolutamide
2
pembrolizumab
1
olaparib
1
gedatolisib
1
enfortumab vedotin
1
Radiation Dose Hypofractionation
1
Pluvicto
1
Mitomycin
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Male Urogenital Diseases
×
Abiraterone Acetate
×
90 days
×
Clear all
NCT06785636
2026-04-24
P300
Pathos AI, Inc.
Phase 1/2
Recruiting
252 enrolled